Prespecified secondary analysis of CONFIDENCE in type 2 diabetes with CKD and albuminuria: hyperkalaemia occurred in 15.1% with empagliflozin plus finerenone, 18.8% with finerenone and 9.7% with empagliflozin; the combination did not significantly reduce risk vs finerenone.
Secondary analysisn = 779
Agarwal et al. Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial